Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00299156 · BASELINE

Baseline characteristics

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome · Source last updated 2015-11-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      32
    2. group Id
      BG001
      value
      17
    3. group Id
      BG002
      value
      16
    4. group Id
      BG003
      value
      65
    units
    Participants
groups
  1. description
    Original dose of 40 mg oral reduced to 30mg and than lower dose of either 10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG000
    title
    Oral Clofarabine
  2. description
    Arm A: 10 mg tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG001
    title
    Randomized, Oral Clofarabine 10mg
  3. description
    Arm B: 20 mg tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG002
    title
    Randomized, Oral Clofarabine 20mg
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          53
          upper Limit
          86
          value
          70.0
        2. group Id
          BG001
          lower Limit
          43
          upper Limit
          87
          value
          67.5
        3. group Id
          BG002
          lower Limit
          54
          upper Limit
          84
          value
          72.5
        4. group Id
          BG003
          lower Limit
          43
          upper Limit
          87
          value
          70.0
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          7
        4. group Id
          BG003
          value
          23
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          23
        2. group Id
          BG001
          value
          10
        3. group Id
          BG002
          value
          9
        4. group Id
          BG003
          value
          42
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
        2. group Id
          BG001
          value
          17
        3. group Id
          BG002
          value
          16
        4. group Id
          BG003
          value
          65
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      32
    2. group Id
      BG001
      value
      17
    3. group Id
      BG002
      value
      16
    4. group Id
      BG003
      value
      65
    units
    Participants
groups
  1. description
    Original dose of 40 mg oral reduced to 30mg and than lower dose of either 10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG000
    title
    Oral Clofarabine
  2. description
    Arm A: 10 mg tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG001
    title
    Randomized, Oral Clofarabine 10mg
  3. description
    Arm B: 20 mg tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
    id
    BG002
    title
    Randomized, Oral Clofarabine 20mg
  4. description
    Total of all reporting groups
    id
    BG003
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          53
          upper Limit
          86
          value
          70.0
        2. group Id
          BG001
          lower Limit
          43
          upper Limit
          87
          value
          67.5
        3. group Id
          BG002
          lower Limit
          54
          upper Limit
          84
          value
          72.5
        4. group Id
          BG003
          lower Limit
          43
          upper Limit
          87
          value
          70.0
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          9
        2. group Id
          BG001
          value
          7
        3. group Id
          BG002
          value
          7
        4. group Id
          BG003
          value
          23
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          23
        2. group Id
          BG001
          value
          10
        3. group Id
          BG002
          value
          9
        4. group Id
          BG003
          value
          42
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
        2. group Id
          BG001
          value
          17
        3. group Id
          BG002
          value
          16
        4. group Id
          BG003
          value
          65
      title
      United States
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice